Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Lung Therapeutics

Lung Therapeutics (LTI) is a biopharmaceutical company developing therapeutics for orphan, unmet needs in lung injury and disease. The Company’s lead drug, LTI-01, is a pro-enzyme for the treatment of Loculated Pleural Effusion (LPE), a severe consequence of pneumonia for which there is no approved pharmacotherapy. In a completed ex-US clinical trial in patients, LTI-01 was demonstrated safe and effective in clearing LPE, resulting in avoidance of surgery and decreased hospitalization. There are no approved drugs for the treatment of LPE. LTI has received US and EU Orphan Drug Designation for LTI-01. The Company’s second drug, LTI-03, is in development for the treatment of idiopathic pulmonary fibrosis (IPF). LTI-03 is a novel peptide addressing a unique mechanism which both promotes epithelial cell survival as well as destruction of fibroblasts. LTI-03 has been proven safe in GLP tox and is ready to enter clinical trials. LTI is raising funding for clinical trials of both drugs.

  • Date:Tuesday, February 12
  • Time:10:30 AM - 10:45 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23449
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:investment
  • Company Website:lungtx.com
  • Company HQ City:Austin
  • Company HQ State:Texas
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$17,000,000
  • Size of Last Investment Round:$14,300,000
  • Previous and Current Investors:Bios Partners, UT Horizon Fund
  • CEO/Top Company Official:Brian Windsor, Ph.D., CEO
  • Year Founded:2013
  • Main Therapeutic Focus:Orphan/Rare Diseases
  • Lead Product in Development:LTI-01
  • Development Phase of Primary Product:Phase II
Speakers
Brian Windsor
Lung Therapeutics
Back